Sanofi announced that it will cut the list price of its U.S. insulin drug, Lantus, by 78% and will cap the cost of the drug at $35 per month for people with private insurance, making it the third major insulin provider to cut costs for consumers.
, the company also said it will cut the list price of its short-acting insulin Apidra by 70%. Sanofi offers uninsured Americans a $35 insulin cap through its Valyou Savings Program.Health advocates have long urged pharmaceutical companies to reduce the cost of insulin, which is relatively inexpensive to manufacture. The companies acted after the Inflation Reduction Act capped Medicare copays for insulin at $35 per month.
. “Sanofi is the latest company to recognize that charging hundreds of dollars for insulin that costs $10 to produce is just wrong, especially when the lives of so many children, parents, and grandparents depend on it.”more than 37 million Americans are living with diabetes and 8.4 million of them rely on insulin to survive. The drug helps regulate blood sugar in people who have type 1 and type 2 diabetes.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78%, the company announced.
Les mer »
Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35Sanofi is cutting the list price of its insulin in the U.S. by 78%, establishing a $35 monthly cap for the privately insured.
Les mer »
Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78%, the company announced.
Les mer »
Sanofi to cut U.S. insulin prices by up to 78%, capping cost at $35Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78%, the company announced.
Les mer »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Les mer »
Sanofi to cut US price of its most-prescribed insulin by 78%Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .
Les mer »